11th April 2011 – Oval Medical Technologies Ltd., the company developing the next generation of autoinjector technology, announced today that they have entered into two deals with pharmaceutical companies who are putting Oval’s primary drug containment technology through feasibility trials. Oval’s CEO Matthew Young has said, ‘These two deals have been signed at a key…

10th January 2011 – Oval Medical Technologies Ltd., the Cambridge based autoinjector company today announced results from two user studies in which Oval’s novel, proprietary autoinjector clearly demonstrated superiority compared with two well-known autoinjector devices currently on the market. The Oval next generation autoinjector is designed to be smaller, easier and safer to use than…

Dr. Catherine Beech talks with Business Editor Jenny Chapman. ‘He’s one of those people who can see a better way of doing things, to make them more useful,” says Dr Catherine Beech, talking about Matthew Young, founder of one of the city’s hottest new companies, Oval Medical Technologies.’

Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was born out of what it saw as a need for radical innovation in the design of autoinjectors.

27th July 2010 – Today, Oval Medical is pleased to announce that the on-going success of developing its revolutionary autoinjector and syringe technologies, has lead to the company’s second expansion less than a year after the company was established.</p> As of July 2010, three new members have joined the team adopting a variety of roles…

Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was born out of what it saw as a need for radical innovation in the design of autoinjectors.

February 12th, 2013 – Oval Medical Technologies Ltd.(“Oval”),  announces that it has signed a further technology assessment contract with a pharmaceutical partner. The drug under investigation is for the treatment of severe infections in patients with chronic lung disease and is expected to be self-injected in a clinical or home setting. The agreement includes a…